EMA Authorised: Rizmoic (naldemedine tosilate) — Shionogi B.V.

View source ↗

Summary

The European Medicines Agency has authorised Rizmoic (naldemedine tosilate) by Shionogi B.V. for constipation. It addresses opioid-induced constipation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• Rizmoic (naldemedine tosilate)

Snippet

Status: Authorised. Therapeutic area: Constipation. MAH: Shionogi B.V.. Decision date: 10/12/2025